A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.

To join this study, adult men and women between 18 and 65 years old are welcome. Women who participate must not be able to become pregnant, either because they have gone through menopause or have had surgery that prevents pregnancy. All participants will need to have a Body Mass Index (BMI) that falls within a specific range, generally between 25 and 39.9, but for those of Japanese or Chinese background, it might be slightly lower, starting at 23. You also need to weigh at least 50 kg (about 7 stone 12 pounds).

There are also specific requirements for participants of Japanese and Chinese descent; they need to have parents and grandparents who are ethnically Japanese or Chinese. This helps researchers understand if the medication works differently in these groups.

However, some conditions would prevent you from taking part. You can't have any serious ongoing medical conditions, particularly those affecting your stomach, liver, or kidneys, or any other health issues that might interfere with how your body handles medications. You also can't have had any significant illnesses, surgeries, or major injuries in the month leading up to the study. If you have a history of serious allergies to similar medications or if you've recently used weight loss medications, you wouldn't be able to join. Lastly, specific mental health conditions like psychosis, bipolar disorder, or major depression would also prevent your participation.

If you decide to take part in this study, you will first go through a screening period that can last up to 5 weeks. During this time, doctors will check your health to make sure the study is suitable for you. This will involve various assessments and tests.

Once you’ve been accepted, you'll enter the 'treatment period'. Depending on the part of the study you're in, you will either receive a single dose of the study medication (AZD1043) or a dummy treatment (placebo), or you will receive multiple doses. You'll be closely monitored by the study team, likely staying at a clinical unit for a period to ensure your safety and to collect important information about how the medication affects you. You will only participate in one part of the study, meaning you will either receive single doses or multiple doses, but not both.

After the treatment period, there will be a 'safety follow-up period'. This is where the study team will continue to monitor your health and well-being for a short time to make sure there are no delayed effects from the medication. Throughout your participation, regular check-ups and assessments will be carried out to keep a close eye on your health. The total duration of your involvement, including screening, treatment, and follow-up, will be explained in detail before you agree to participate.